Autoimmune co Tolarex gets NIS 3.5m grant

Feb. 21, 2010
Source: Yaniv Magal and Shmulik Shelah, Globes [online], Israel business news

Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company Tolarex Ltd. has obtained a NIS 3.5 million grant from the Office of the Chief Scientist. Tolarex is developing an autoimmune therapy for graft versus host disease, in which the body rejects implants.

Hadasit Bio is a subsidiary of Hadasit - the Technology Transfer Company of Hadassah Medical Organization .

News Archive

Did You Know?

The Hebrew University ranks 12^th worldwide in biotechnology patents.
$1 billion in annual sales are generated from two life science products originating from scientific innovation in Jerusalem. These include Exelon (HUJ and Novartis) for the treatment of Alzheimer’s disease and Doxil (HUJ and J&J/Schering) for the treatment of cancer.


© BIOJERUSALEM. All Rights Reserved.	Back to Top